BioNTech (NASDAQ:BNTX - Get Free Report) released its earnings results on Monday. The company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.70, RTT News reports. The company had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business's revenue for the quarter was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.90 EPS. BioNTech updated its FY 2025 guidance to EPS.
BioNTech Stock Performance
Shares of BNTX stock traded down $2.85 during trading hours on Thursday, reaching $97.46. 677,025 shares of the company's stock were exchanged, compared to its average volume of 807,990. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $23.37 billion, a P/E ratio of -46.41 and a beta of 0.30. The business has a fifty day moving average price of $116.18 and a 200-day moving average price of $113.04.
Analyst Ratings Changes
A number of brokerages recently commented on BNTX. BMO Capital Markets boosted their price objective on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research report on Tuesday. HC Wainwright reaffirmed a "buy" rating and issued a $150.00 price target on shares of BioNTech in a research note on Monday, November 18th. Wells Fargo & Company initiated coverage on BioNTech in a report on Wednesday, December 11th. They set an "overweight" rating and a $170.00 price objective for the company. Berenberg Bank began coverage on BioNTech in a research note on Tuesday, November 19th. They issued a "buy" rating and a $130.00 target price on the stock. Finally, Truist Financial initiated coverage on BioNTech in a report on Friday, January 10th. They issued a "buy" rating and a $172.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $143.73.
Get Our Latest Stock Report on BioNTech
BioNTech Company Profile
(
Get Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
See Also

Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.